Cargando…

Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer

Brain metastases (BM) in patients with thyroid cancer (TC) are rare with an incidence of 1% for papillary and follicular, 3% for medullary and up to 10% for anaplastic TC (PTC, FTC, MTC and ATC). Little is known about the characteristics and management of BM from TC. Thus, we retrospectively analyze...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolff, Ladislaia, Steindl, Ariane, Popov, Petar, Dieckmann, Karin, Gatterbauer, Brigitte, Widhalm, Georg, Berghoff, Anna Sophie, Preusser, Matthias, Raderer, Markus, Kiesewetter, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232560/
https://www.ncbi.nlm.nih.gov/pubmed/37219741
http://dx.doi.org/10.1007/s10585-023-10208-8
_version_ 1785052009255141376
author Wolff, Ladislaia
Steindl, Ariane
Popov, Petar
Dieckmann, Karin
Gatterbauer, Brigitte
Widhalm, Georg
Berghoff, Anna Sophie
Preusser, Matthias
Raderer, Markus
Kiesewetter, Barbara
author_facet Wolff, Ladislaia
Steindl, Ariane
Popov, Petar
Dieckmann, Karin
Gatterbauer, Brigitte
Widhalm, Georg
Berghoff, Anna Sophie
Preusser, Matthias
Raderer, Markus
Kiesewetter, Barbara
author_sort Wolff, Ladislaia
collection PubMed
description Brain metastases (BM) in patients with thyroid cancer (TC) are rare with an incidence of 1% for papillary and follicular, 3% for medullary and up to 10% for anaplastic TC (PTC, FTC, MTC and ATC). Little is known about the characteristics and management of BM from TC. Thus, we retrospectively analyzed patients with histologically verified TC and radiologically verified BM identified from the Vienna Brain Metastasis Registry. A total of 20/6074 patients included in the database since 1986 had BM from TC and 13/20 were female. Ten patients had FTC, 8 PTC, one MTC and one ATC. The median age at diagnosis of BM was 68 years. All but one had symptomatic BM and 13/20 patients had a singular BM. Synchronous BM at primary diagnosis were found in 6 patients, while the median time to BM diagnosis was 13 years for PTC (range 1.9–24), 4 years for FTC (range 2.1–41) and 22 years for the MTC patient. The overall survival from diagnosis of BM was 13 months for PTC (range 1.8–57), 26 months for FTC (range 3.9–188), 12 years for the MTC and 3 months for the ATC patient. In conclusion, development of BM from TC is exceedingly rare and the most common presentation is a symptomatic single lesion. While BM generally constitute a poor prognostic factor, individual patients experience long-term survival following local therapy.
format Online
Article
Text
id pubmed-10232560
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-102325602023-06-02 Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer Wolff, Ladislaia Steindl, Ariane Popov, Petar Dieckmann, Karin Gatterbauer, Brigitte Widhalm, Georg Berghoff, Anna Sophie Preusser, Matthias Raderer, Markus Kiesewetter, Barbara Clin Exp Metastasis Research Paper Brain metastases (BM) in patients with thyroid cancer (TC) are rare with an incidence of 1% for papillary and follicular, 3% for medullary and up to 10% for anaplastic TC (PTC, FTC, MTC and ATC). Little is known about the characteristics and management of BM from TC. Thus, we retrospectively analyzed patients with histologically verified TC and radiologically verified BM identified from the Vienna Brain Metastasis Registry. A total of 20/6074 patients included in the database since 1986 had BM from TC and 13/20 were female. Ten patients had FTC, 8 PTC, one MTC and one ATC. The median age at diagnosis of BM was 68 years. All but one had symptomatic BM and 13/20 patients had a singular BM. Synchronous BM at primary diagnosis were found in 6 patients, while the median time to BM diagnosis was 13 years for PTC (range 1.9–24), 4 years for FTC (range 2.1–41) and 22 years for the MTC patient. The overall survival from diagnosis of BM was 13 months for PTC (range 1.8–57), 26 months for FTC (range 3.9–188), 12 years for the MTC and 3 months for the ATC patient. In conclusion, development of BM from TC is exceedingly rare and the most common presentation is a symptomatic single lesion. While BM generally constitute a poor prognostic factor, individual patients experience long-term survival following local therapy. Springer Netherlands 2023-05-23 2023 /pmc/articles/PMC10232560/ /pubmed/37219741 http://dx.doi.org/10.1007/s10585-023-10208-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Paper
Wolff, Ladislaia
Steindl, Ariane
Popov, Petar
Dieckmann, Karin
Gatterbauer, Brigitte
Widhalm, Georg
Berghoff, Anna Sophie
Preusser, Matthias
Raderer, Markus
Kiesewetter, Barbara
Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
title Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
title_full Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
title_fullStr Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
title_full_unstemmed Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
title_short Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
title_sort clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232560/
https://www.ncbi.nlm.nih.gov/pubmed/37219741
http://dx.doi.org/10.1007/s10585-023-10208-8
work_keys_str_mv AT wolffladislaia clinicalcharacteristicstreatmentandlongtermoutcomeofpatientswithbrainmetastasesfromthyroidcancer
AT steindlariane clinicalcharacteristicstreatmentandlongtermoutcomeofpatientswithbrainmetastasesfromthyroidcancer
AT popovpetar clinicalcharacteristicstreatmentandlongtermoutcomeofpatientswithbrainmetastasesfromthyroidcancer
AT dieckmannkarin clinicalcharacteristicstreatmentandlongtermoutcomeofpatientswithbrainmetastasesfromthyroidcancer
AT gatterbauerbrigitte clinicalcharacteristicstreatmentandlongtermoutcomeofpatientswithbrainmetastasesfromthyroidcancer
AT widhalmgeorg clinicalcharacteristicstreatmentandlongtermoutcomeofpatientswithbrainmetastasesfromthyroidcancer
AT berghoffannasophie clinicalcharacteristicstreatmentandlongtermoutcomeofpatientswithbrainmetastasesfromthyroidcancer
AT preussermatthias clinicalcharacteristicstreatmentandlongtermoutcomeofpatientswithbrainmetastasesfromthyroidcancer
AT raderermarkus clinicalcharacteristicstreatmentandlongtermoutcomeofpatientswithbrainmetastasesfromthyroidcancer
AT kiesewetterbarbara clinicalcharacteristicstreatmentandlongtermoutcomeofpatientswithbrainmetastasesfromthyroidcancer